SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
DE |
|
Suryamas Dutamakmur Tbk PT
IDX:SMDM
|
ID |
|
Kaisa Prosperity Holdings Ltd
HKEX:2168
|
CN |
|
Ooma Inc
NYSE:OOMA
|
US |
|
Y
|
YPF SA
BCBA:YPFD
|
AR |
|
Red Star Macalline Group Corp Ltd
SSE:601828
|
CN |
|
C
|
Cuscapi Berhad
KLSE:CUSCAPI
|
MY |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
KY |
|
C
|
Castellum Inc
AMEX:CTM
|
US |
|
G
|
Globex Mining Enterprises Inc
OTC:GLBXF
|
CA |
Wall Street
Price Targets
1SXP Price Targets Summary
SCHOTT Pharma AG & Co KgaA
According to Wall Street analysts, the average 1-year price target for
1SXP
is 19.93 EUR
with a low forecast of 13.13 EUR and a high forecast of 27.2 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is 1SXP's stock price target?
Price Target
19.93
EUR
According to Wall Street analysts, the average 1-year price target for
1SXP
is 19.93 EUR
with a low forecast of 13.13 EUR and a high forecast of 27.2 EUR.
What is SCHOTT Pharma AG & Co KgaA's Revenue forecast?
Projected CAGR
6%
For the last 4 years the
compound annual growth rate for
SCHOTT Pharma AG & Co KgaA's revenue is
11%.
The projected
CAGR
for the next 3 years is
6%.
What is SCHOTT Pharma AG & Co KgaA's Operating Income forecast?
Projected CAGR
9%
For the last 4 years the
compound annual growth rate for
SCHOTT Pharma AG & Co KgaA's operating income is
13%.
The projected
CAGR
for the next 3 years is
9%.
What is SCHOTT Pharma AG & Co KgaA's Net Income forecast?
Projected CAGR
8%
For the last 4 years the
compound annual growth rate for
SCHOTT Pharma AG & Co KgaA's net income is
10%.
The projected
CAGR
for the next 3 years is
8%.
